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Resistant hypertension is characterised by failure to 
achieve a blood pressure of less than 140/90 mm Hg 
while on maximum tolerated doses of three diﬀ erent 
classes of antihypertensive drugs, including a diuretic 
appropriate for kidney function.1 While often ascribed 
to medication non-adherence,2 true resistant cases of 
hypertension are linked to non-adherence to lifestyle 
modiﬁ cations to control blood pressure, including 
low sodium diet, reduced alcohol ingestion, and 
weight reduction.3 
Several pharmacological regimens to treat such patients 
have inconsistent outcomes. It has been posited that 
the sympathetic nervous system and excess sodium 
intake are the principal drivers of resistant hypertension.4 
Despite this, targeted therapies, based on both 
pharmacological approaches (ie, α–β blockers) and devices 
(ie, renal denervation), have generated disappointing 
results.4 Other adjuvant therapies include aldosterone 
antagonists such as spironolactone.5 These drugs have 
a plausible physiological basis because the prevalence 
of hyperaldosteronism is higher than previously 
appreciated and the phenomenon of aldosterone 
so-called escape exists after long-term renin–angiotensin 
system blockade.6 Although spironolactone has proven 
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safe abortion are restricted, girls who become pregnant 
outside marriage might believe that self-harm or suicide 
are their only alternatives.11,12
Related to the phenomenon of early pregnancy is 
child marriage, which aﬀ ects around 40 000 girls under 
the age of 18 years every day.13 Child brides are typically 
removed from their families, peers, and educational 
opportunities, and face higher rates of unintended 
pregnancy, domestic violence, and sexually transmitted 
infections than their unmarried peers. Although few 
studies have assessed the mental health eﬀ ects of 
child marriage, one study in the USA found that child 
marriage was associated with high rates of long-term 
psychiatric disorders.14
Donor funding structures and the manner in which 
global health is currently addressed do not support 
the type of cross-cutting and multidisciplinary 
research that is needed to truly understand and 
stem the scourge of suicide among adolescent girls. 
Funding must be made available to catalyse research, 
programmes, and policy dialogues addressing the 
many sided nature of the challenge, with a particular 
focus on the role that harmful gender norms 
might have. We need improved monitoring and 
documentation of suicides and suicide attempts, and 
greater innovation in promoting mental health among 
adolescents. And as we move toward a new global 
development agenda and a new global strategy on the 
health of women, children, and adolescents, we must 
address the full range of health needs for adolescent 
girls, a crucial and previously neglected population.
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superior to renal denervation in some treatment studies, 
head-to-head trials are lacking.7,8
In The Lancet, Bryan Williams and colleagues9 report 
on the PATHWAY-2 study that investigates the eﬀ ect 
of spironolactone versus placebo, and two other 
drugs, bisoprolol and doxazosin, in a randomised, 
double-blind, crossover trial to determine which drug 
produced the greatest reduction in blood pressure 
when added to a pre-existing three-drug regimen. 
The authors hypothesised that resistant hypertension, 
driven by sodium retention, would be best managed by 
adjuvant diuretic therapy—ie, spironolactone. To this 
end a surrogate for sodium status, plasma renin, was 
assessed in an attempt to predict those most responsive 
to spironolactone-based therapies. 
After conﬁ rmation of the presence of systolic 
blood pressures in excess of 130 mm Hg at home and 
140 mm Hg in the clinic, and exclusion of those patients 
with advanced kidney disease, 335 individuals were 
randomised to a sequence comprising spironolactone 
(ﬁ nal dose 50 mg, n=285), bisoprolol (ﬁ nal dose 
10 mg, n=285), doxazosin (ﬁ nal dose 8 mg, n=282), 
or placebo (n=274) for 12 weeks. After each treatment 
cycle, patients were treated sequentially with the 
remaining drugs, each for an additional 12-week 
period, with doses force-titrated (doubled) at 6 weeks. 
230 patients received both doses of all treatments. The 
trial’s primary endpoint was the diﬀ erence in average 
home systolic blood pressure between spironolactone 
and placebo, followed if signiﬁ cant by diﬀ erences in 
home systolic blood pressure between spironolactone 
and the mean of the other two drugs, followed by the 
other two drugs individually.
In terms of diﬀ erence in average home systolic blood 
pressure, spironolactone was superior to placebo 
(–8·70 mm Hg [95% CI –9·72 to –7·69]), to the mean of 
doxazosin and bisoprolol (–4·26 [–5·13 to –3·38]), and 
to doxazosin (–4·03 [–5·04 to –3·02]) and bisoprolol 
(–4·48 [–5·50 to –3·46]) individually. Upon study 
termination, 58% of spironolactone treated patients 
achieved blood pressure control versus about 42% of 
doxazosin, and 43% of bisoprolol patients. There was 
an inverse and linear relationship between renin and 
blood pressure response to spironolactone, a ﬁ nding 
not seen with bisoprolol or doxazosin. Serious adverse 
event rates, including hyperkalaemia, were less than 3% 
in each group.
Williams and colleagues9 provide the strongest 
support yet for the antihypertensive eﬃ  cacy of 
spironolactone in cases of resistant hypertension. The 
mandatory use of pretrial diuretics and the assessment 
of clinic and home blood pressures allow the authors to 
exclude patients with so-called white coat hypertension. 
The implementation of renin proﬁ ling, previously 
shown to predict responsiveness to diuretics,10 was an 
accurate predictor of spironolactone response.
Despite these promising results, there are limitations 
to extrapolation of the results of PATHWAY-2 to the 
general population. The study design does not exclude 
a carry-over eﬀ ect, because there were no interval 
washout periods between drugs, but the authors noted 
almost identical diﬀ erences between drugs when only 
the ﬁ rst cycle treatments were compared in a parallel 
group fashion (appendix p 16).9 In view of the duration 
of spironolactone activity, this extended eﬀ ect would 
be advantageous to the comparator drugs; however, 
treatment with spironolactone yielded about a 6 mm Hg 
greater reduction in systolic blood pressure compared 
with bisoprolol or doxazosin at 12 weeks. Additionally, 
there was a 4 mm Hg diﬀ erence favouring spironolactone 
in the primary comparisons of average systolic blood 
pressure on low and high doses. Would similar results 
be achieved in an African-American or Afro-Caribbean 
cohort? Can these results be applied to patients with 
advanced kidney disease at risk for hyperkalaemia? 
Would people with much lower sodium intake than 
those participating in this study, in whom 24-h urine 
sodium was about 137 mmol/L (8 g), still require addition 
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Catheter-related bloodstream infections were once 
viewed as an inescapable consequence of prov iding care 
to critically ill patients. It was not until the beginning of 
the 21st century that a conceptual model identiﬁ ed both 
technical and socioadaptive strategies to prevent this 
outcome.1 Key among technical factors were processes 
such as skin disinfection with chlorhexidine and use 
of large drapes at the time of insertion to prevent 
catheter contamination. Conversely, socioadaptive 
factors were focused on behavioural aspects such 
as adhering to proper hand hygiene, nurse-led halts 
if parts of sterile insertion were not followed, and 
targeting of unit-speciﬁ c culture to increase compliance. 
Although closely intertwined, combining technical and 
socioadaptive factors within a bundle of best practices 
has substantially reduced catheter-related bloodstream 
infections in the past decade.2
But which elements of this bundle are most 
responsible for reducing catheter infections? This 
question is not merely a point of academic debate, but 
one that has important clinical and policy ramiﬁ cations. 
For example, empowering nurses to stop physicians if 
hand hygiene before catheter insertion is not performed 
or speciﬁ c sterile technique is not followed requires 
changes in social norms and organisational culture. 
Such initiatives are diﬃ  cult and might distract from 
more eﬃ  cient preventive measures if not eﬀ ective. 
Alternatively, if a technical factor such as chlorhexidine 
is most responsible for reductions in bloodstream 
infection, then implementation of a chlorhexidine-only 
Vascular catheter infections: time to get technical
of spironolactone? Additionally, would a longer acting 
thiazide diuretic such as chlorthalidone or indapamide 
reduce the need for spironolactone? Lastly, the average 
weight of participants in Williams and colleagues’ cohort 
was around 94 kg, generally less than that in some areas 
of the world. Future studies need to address these issues.
PATHWAY-29 makes the addition of spironolactone to 
a three-drug regimen hard to resist in cases of resistant 
hypertension among overweight patients with stages 
1 and 2 kidney disease. Newer aldosterone antagonists 
such as ﬁ nerenone with less risk of hyperkalaemia11 and 
potassium binders, such as patiromer,12 will be available 
soon, to aid in reducing the risk of hyperkalaemia in the 
subset of resistant hypertensive patients with stage 3B 
or higher kidney disease. PATHWAY-2 provides strong 
evidence for an approach to conquer the problem of 
resistant hypertension in the general population.
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